- Bausch Health Canada’s PrOKEDI (risperidone) 75 mg and 100 mg is now listed on Quebec’s RAMQ drug formulary for adults with schizophrenia, effective June 25, 2026.
- PrOKEDI is a once-monthly long-acting injectable that reaches therapeutic levels within hours and requires no loading dose or oral supplementation.
- The Quebec reimbursement follows the company’s earlier pCPA negotiations, with efforts ongoing to secure coverage in other provinces.
- Bausch said the listing expands treatment options for people living with schizophrenia and supports broader access to innovative mental health therapies.
Takeaways:
Quebec’s listing of PrOKEDI on the RAMQ formulary is a key commercial milestone for Bausch Health, turning a specialized, once‑monthly long‑acting risperidone into a publicly funded option for adults with schizophrenia in Canada’s second‑largest drug plan jurisdiction. Because PrOKEDI hits therapeutic levels quickly and needs no loading dose or oral supplementation, it addresses major adherence and logistical barriers that often limit use of long‑acting injectables, which should make it easier to prescribe and more attractive to hospitals and community programs.
Source: CA Newswire
